Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Metastasis | Review

Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis

Authors: Dingding Wang, Hong Zhang, Xiaolian Fang, Xue Zhang, Honggang Liu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

A number of studies have demonstrated the critical role of long non-coding RNA gastric cancer high expressed transcript 1 (GHET1) in many cancers. This meta-analysis provides an evidence-based evaluation of the prognostic role of GHET1 in cancer.

Materials and methods

Literature searches were conducted in several databases including Medline, Cochrane, EMBASE, CNKI, and Wanfang. The pooled odds ratio (OR) and hazard ratio (HR) with 95% confidence interval (CI) were used to evaluate the role of GHET1 in cancer. The study protocol was registered at PROSPERO (ID: CRD42018111252).

Results

Sixteen studies, containing 1315 patients, were analyzed in this meta-analysis. The pooled results indicated that GHET1 overexpression was significantly associated with poor overall survival (OS) and disease-free survival (DFS) in cancer. Moreover, up-regulation of GHET1 expression predicted larger tumor size, positive lymph node metastasis, positive distant metastasis, and advanced TNM (tumor-node-metastases) stage in human cancers.

Conclusion

There is a significant correlation between up-regulation of GHET1 and both poor prognosis and advanced clinicopathological cancer characteristics. GHET1 may be a potential prognostic predictor for human cancers.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
Ng L, Poon RT, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. CMLS. 2013;70(19):3631–56.CrossRef
3.
Kim JL, Cho KH, Park EC, Cho WH. A single measure of cancer burden combining incidence with mortality rates for worldwide application. APJCP. 2014;15(1):433–9.PubMed
4.
Qin L, Chen C, Chen L, Xue R, Ou-Yang M, Zhou C, Zhao S, He Z, Xia Y, He J, et al. Worldwide malaria incidence and cancer mortality are inversely associated. Infect Agents Cancer. 2017;12:14.CrossRef
5.
Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579–89.CrossRef
6.
Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2017;28(4):287–301.CrossRef
7.
Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45(8):1895–910.CrossRef
8.
Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochem Biophys Acta. 2014;1839(11):1097–109.PubMed
9.
Dhamija S, Diederichs S. From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis. Int J Cancer. 2016;139(2):269–80.CrossRef
10.
Bhan A, Mandal SS. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. Biochem Biophys Acta. 2015;1856(1):151–64.PubMed
11.
Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, Yang H, Sun J. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 2015;34:102.CrossRef
12.
Giulietti M, Righetti A, Principato G, Piva F. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer. Carcinogenesis. 2018;39(8):1016–25.CrossRef
13.
Ning L, Li Z, Wei D, Chen H, Yang C. LncRNA, NEAT1 is a prognosis biomarker and regulates cancer progression via epithelial-mesenchymal transition in clear cell renal cell carcinoma. Cancer Biomarkers. 2017;19(1):75–83.CrossRef
14.
Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y, Fang G. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 2014;281(3):802–13.CrossRef
15.
Zhou HY, Zhu H, Wu XY, Chen XD, Qiao ZG, Ling X, Yao XM, Tang JH. Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer. Eur Rev Med Pharm Sci. 2017;21(22):5081–8.
16.
Zhang X, Bo P, Liu L, Zhang X, Li J. Overexpression of long non-coding RNA GHET1 promotes the development of multidrug resistance in gastric cancer cells. Biomed Pharm. 2017;92:580–5.CrossRef
17.
Liu H, Zhen Q, Fan Y. LncRNA GHET1 promotes esophageal squamous cell carcinoma cells proliferation and invasion via induction of EMT. Int J Biol Markers. 2017;32(4):e403–8.CrossRef
18.
Li LJ, Zhu JL, Bao WS, Chen DK, Huang WW, Weng ZL. Long noncoding RNA GHET1 promotes the development of bladder cancer. Int J Clin Exp Pathol. 2014;7(10):7196–205.PubMedPubMedCentral
19.
Guan ZB, Cao YS, Li Y, Tong WN, Zhuo AS. Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomarkers. 2018;21(3):557–63.CrossRef
20.
Ding G, Li W, Liu J, Zeng Y, Mao C, Kang Y, Shang J. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. Biomed Pharm. 2017;94:326–31.CrossRef
21.
Xia Y, Yan Z, Wan Y, Wei S, Bi Y, Zhao J, Liu J, Liao DJ, Huang H. Knockdown of long noncoding RNA GHET1 inhibits cellcycle progression and invasion of gastric cancer cells. Mol Med Rep. 2018;18(3):3375–81.PubMedPubMedCentral
22.
Song R, Zhang J, Huang J, Hai T. Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition. Cancer Biomarkers. 2018;22(3):565–73.CrossRef
23.
Shen QM, Wang HY, Xu S. LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer. Eur Rev Med Pharm Sci. 2018;22(8):2328–33.
24.
Jin L, He Y, Tang S, Huang S. LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. J Cell Physiol. 2018;233(6):4726–34.CrossRef
25.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.CrossRef
26.
Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett. 2013;339(2):159–66.CrossRef
27.
Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 2017;548(7667):343–6.CrossRef
28.
Bassett AR, Akhtar A, Barlow DP, Bird AP, Brockdorff N, Duboule D, Ephrussi A, Ferguson-Smith AC, Gingeras TR, Haerty W, et al. Considerations when investigating lncRNA function in vivo. eLife. 2014;3:e03058.CrossRef
29.
Iwakiri J, Hamada M, Asai K. Bioinformatics tools for lncRNA research. Biochem Biophys Acta. 2016;1859(1):23–30.PubMed
30.
Shibayama Y, Fanucchi S, Magagula L, Mhlanga MM. lncRNA and gene looping: what’s the connection? Transcription. 2014;5(3):e28658.CrossRef
31.
Zhou J, Li X, Wu M, Lin C, Guo Y, Tian B. Knockdown of long noncoding RNA GHET1 inhibits cell proliferation and invasion of colorectal cancer. Oncol Res. 2016;23(6):303–9.CrossRef
32.
Yang Z, Wang R, Zhang T, Dong X. Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer. Int J Clin Exp Med. 2015;8(11):19954–68.PubMedPubMedCentral
33.
Xie W, Chen Q, Liu X, Ma M, Yang X, Gong B, Sun T, Chen J. Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. Oncol Lett. 2019;17(3):3173–80.PubMedPubMedCentral
34.
Yang W, Shan Z, Zhou X, Peng L, Zhi C, Chai J, Liu H, Yang J, Zhang Z. Knockdown of lncRNA GHET1 inhibits osteosarcoma cells proliferation, invasion, migration and EMT in vitro and in vivo. Cancer Biomarkers. 2018;23(4):589–601.CrossRef
35.
Huang H, Liao W, Zhu X, Liu H, Cai L. Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer. Biomed Pharm. 2017;92:562–8.CrossRef
36.
Ni W, Luo L, Zuo P, Li RP, Xu XB, Wen F, Hu D. lncRNA GHET1 down-regulation suppresses the cell activities of glioma. Cancer Biomarkers. 2018;23(1):9–22.CrossRef
Metadata
Title
Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis
Authors
Dingding Wang
Hong Zhang
Xiaolian Fang
Xue Zhang
Honggang Liu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01189-9

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Linc00473 potentiates cholangiocarcinoma progression by modulation of DDX5 expression via miR-506 regulation

Primary research

MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma

Correction

Correction to: Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression

Primary research

circ_0084927 promotes cervical carcinogenesis by sponging miR-1179 that suppresses CDK2, a cell cycle-related gene

Primary research

Inhibition of let-7b-5p contributes to an anti-tumorigenic macrophage phenotype through the SOCS1/STAT pathway in prostate cancer

Primary research

Molecular interaction and cellular studies on combination photodynamic therapy with rutoside for melanoma A375 cancer cells: an in vitro study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits